ISOPTO – MAXITROL EYE DROPS 5 ML

* ISOPTO-MAXITROL Sterile Eye (Ophthalmic) Preparation. 5 ml Drop-Trainer Dispenser.
* Composition (Ingredients):
Active: Neomycin (present as Sulfate) 3.5 mg/mL, Polymyxin B Sulfate 6,000 units/mL, Dexamethasone 0.1%.
Vehicle: Hydroxypropyl Methylcellulose (4,000 cps) 0.5%.
Preservative: Benzalkonium Chloride 0.004%.
* Indications:
& Eye: In the management of infectious ocular inflammations produced by organisms which are sensitive
& to the antibiotics, Neomycin Sulfate and Polymyxin B sulfate. Acute or chronic nonpurulent conjunctivitis,
& blepharoconjunctivitis and keratoconjunctivitis; nonspecific superficial keratitis; deep keratitis; acne
& rosacea keratitis; iridocyclitis mild acute iritis; recurrent marginal ulceration and corneal ulcer (use with
& care in those diseases causing thinning of cornea because of the danger of proliferation); nonpurulent
& blepharitis; scleritis; episcleritis; scleroconjunctivitis; herpes zoster ophthalmicus (do not use in Herpes
& simplex); and post-operatively to aid in the prevention of ophthalmic cases of infections.
* Contraindications:
& This drug is contraindicated in tuberculosis, fungal and most viral lesions of eye (herpes simplex/dentritic
& keratitis); varicella; acute purulent conjunctivitis and acute purulent blepharitis, aural fungal infection.
* Precautions:
– Extended use of topical steroid therapy may cause increased intraocular pressure in certain individuals.
& It is desirable that intraocular pressure be checked frequently.
– In those diseases causing thinning of the cornea, perforation has been known to occur with the use of
& topical steroids.
– Prolonged use may result in overgorwth of non-susceptible organisms, including fungi. Appropriate measures
& should be taken when this occurs. A few individuals may be sensitive to one or more components of this
& product. If any reactions indicating sensitivity are observed, discontinue use.
– Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of
& their use in pregnancy has not absolutely been established. Therefore it is not advisable to use this product
& for long-term treatments of pregnant patients.
* Dosage and Administration:
& Eye: one or two drops topically in the conjunctival sac(s) 4 to 6 times daily. Dosage may be reduced after
& 3 to 4 days when satisfactory improvement has been obtained. Treatment should be repeated as long as
& necessary following physician’s advice.
* Shake Well Before Using.
* Store upright. Do not store above 25 degrees C. Do not refrigerate or freeze.